How long is the study?
A maximum of 24 weeks (about six months). Treatment is up to 12 weeks with an additional 12-week follow-up.
Complete this brief questionnaire
Check eligibilityThis study is looking for individuals (ages 18-80) with immune-mediated thrombotic thrombocytopenic purpura (iTTP). Sanofi believes that everyone should have the opportunity to participate in clinical trials, especially those that have been historically under-represented.
What is the purpose of the study?
The purpose of this study is to evaluate the safety and effectiveness of caplacizumab and immunosuppressive drugs without TPE by measuring the proportion of patients who achieve remission (no signs and symptoms of iTTP and iTTP related blood markers are in the normal range) without requiring therapeutic plasma exchange.
A maximum of 24 weeks (about six months). Treatment is up to 12 weeks with an additional 12-week follow-up.
A maximum of 15 visits to the study clinic, following initial hospitalization.
No, all things study-related are provided, including study-related exams, study-related medications and other study-related medical care. There is no insurance required to participate. All study-related medical care will be explained. Study-related exams may include:
Yes, after you complete the online questionnaire and give permission to be contacted, a study representative will contact with you. You can ask questions at any time, before deciding to participate and during study conduct.
Complete this brief questionnaire to help determine if you may qualify to be referred to a site recruiting in your area for further evaluation for potential participation in this clinical study.
You can also add your contact information to be notified of future Sanofi studies.